Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).
Aim(s): The aim of this work is to assess if cumulative dose and dose intensity of everolimus may affect survival of advanced pNETs patients (pts).
Materials and methods: 111 pts (M/F=62/49,median age 54 years) were treated with everolimus for ≥3 months. Cumulative dose (CD) was defined as the total amount of everolimus taken by the pts despite delay or dose reductions; Dose Intensity (DI) was defined as everolimus dose delivered per time unit (mg/day) taken by the pts in a given period of time. According to a ROC analysis, pts were stratified into two groups, with CD<1500 mg (Group A) and CD≥1500 mg (Group B).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Prof. Rossana Berardi
, Torniai M
, Pusceddu S
, Spada F
, Brizzi M P
, Ibrahim T
, Antonuzzo L
, Ferolla P
, Panzuto F
, Silvestris N
, Partelli S
, Bongiovanni A
, Zichi C
, Riva N
, Rinzivillo M
To read results and conclusion, please login ...
Further abstracts you may be interested in